Design Issues in Randomized Phase II/III Trials
- 20 February 2012
- journal article
- statistics in-oncology
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 30 (6) , 667-671
Abstract
Phase II trials are used to show sufficient preliminary activity of a new treatment (in single-arm designs or randomized screening designs) or to select among treatments with demonstrated activity (in randomized selection designs). The treatments prioritized in a phase II trial are then tested definitively against a control treatment in a randomized phase III trial. Randomized phase II/III trials use an adaptive trial design that combines these two types of trials in one, with potential gains in time and reduced numbers of patients required to be treated. Two key considerations in designing a phase II/III trial are whether to suspend accrual while the phase II data mature and the choice of phase II target treatment effect. We discuss these phase II/III design parameters, give examples of phase II/III trials, and provide recommendations concerning efficient phase II/III trial designs.Keywords
This publication has 23 references indexed in Scilit:
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerNew England Journal of Medicine, 2011
- Designs for clinical trials with time-to-event outcomes based on stopping guidelines for lack of benefitTrials, 2011
- A general inefficacy interim monitoring rule for randomized clinical trialsClinical Trials, 2010
- A Comparison of Phase II Study StrategiesClinical Cancer Research, 2009
- Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroupJournal of Clinical Oncology, 2009
- Monitoring for Lack of Benefit: A Critical Component of a Randomized Clinical TrialJournal of Clinical Oncology, 2009
- Speeding up the Evaluation of New Agents in CancerJNCI: Journal of the National Cancer Institute, 2008
- Multi-Arm Clinical Trials of New Agents: Some Design ConsiderationsClinical Cancer Research, 2008
- Optimal two-stage screening designs for survival comparisonsBiometrika, 1990
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989